1 Determinants of anti-retroviral therapy adherence among adolescents living

2 with HIV in the Kingdom of Eswatini

- 3
- 4 Londiwe D. Hlophe^{1*}, Constance S. Shumba², Diribsa T. Bedada^{1,3}, Peter S.
- 5 Nyasulu^{1,4*}
- 6
- 7 Affiliations
- ⁸ ¹ Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences,
- 9 Stellenbosch University, Cape Town, South Africa
- ² School of Nursing and Midwifery, Aga Khan University, Nairobi, Kenya
- ³ Department of Public Health, College of Health Sciences, National Defence
- 12 University, Addis Ababa, Ethiopia
- ⁴ Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health
- 14 Sciences, University of the Witwatersrand, Johannesburg, South Africa
- 15
- ¹⁶ ^{*}Corresponding authors
- 17 Email: londiwehlope85@gmail.com (LDH)
- 18 pnyasulu@sun.ac.za (PSN)

19

20

21 Abstract

Background: The success of antiretroviral therapy (ART) depends on a high level of 22 adherence to the life-long therapy of 95% and above. However, in Eswatini, 23 adolescents and young people aged 15 to 24 years, have poor ART adherence as 24 evidenced by low viral load (VL) suppression rates (76% and 63% among female and 25 males respectively) compared to the general population (96%). The wide age-band of 26 15 to 24 years in reporting viral suppression rates means that adolescent specific data 27 is limited, and younger adolescents aged 10-14 years are excluded. This study 28 explored the level of ART adherence and associated factors among adolescents living 29 with HIV (ALHIV) aged 10 to 19 years on ART in Eswatini. 30

Methods: We performed a retrospective analysis of 911 medical records of ALHIV aged 10 to 19 years on ART for at least a month in Eswatini for the period 1st January 2017 to 30th September 2022. Bivariate logistic regression was fitted for each predictor variable. Missing values were imputed using multiple imputation by chained equation (MICE). Statistically significant (p-value ≤ 0.2) predictor variables were included in a multivariable logistic regression model. P-value ≤ 0.05 was used to declare statistical significance in the final regression model.

Results: ART adherence of 88.5% was recorded with higher adherence among males (88.9%) than females (87.8%). Hhohho region had highest adherence (90.7%) while Shiselweni region had lowest adherence (82%). Adherence was low among ALHIV with a non-suppressed baseline VL result (65.3%) and those assigned to multi-month ART model of care at ART initiation (66.7%). The Shiselweni region (OR 0.47; 95%CI 0.26-2.78), suppressed baseline VL result (OR 5.49; 95%CI 3.36-8,96) and assigned to the main-stream ART care model (OR 0.22; 95%CI 0.05-0.95) were statistically

associated with ART adherence. In the multivariable regression analysis, only
Shiselweni region and suppressed baseline VL result were statistically associated with
ART adherence.

Conclusion: Eswatini ALHIV have a low ART adherence compared to general population. Shiselweni region is negatively associated with ART adherence among ALHIV while a suppressed baseline VL is positively associated with improved ART adherence. There is therefore a need to intensify interventions aimed at early ART initiation and intensive follow-up and support among ALHIV especially in the Shiselweni region.

Keywords: ART adherence; viral load suppression; adolescents living with HIV;
Kingdom of Eswatini

- -

66 **1. Background**

Globally, commendable strides have been made in attaining an optimum antiretroviral
therapy (ART) adherence rate, and accordingly achieving viral load suppression (VLS)
among people living with HIV (PLHIV). For instance, in the year 2021, 75% of PLHIV
were on ART and 68% of these were virally suppressed [1,2]. In eastern and southern
Africa which is home to 54% of all PLHIV globally, 79% of PLHIV were on ART, and
of these, 78% were virally suppressed in 2021 [3,4].

ART adherence is defined as "the extent to which a personal behaviour in taking HIV 73 medication, attending scheduled clinic appointments, following a diet or certain 74 behaviour corresponds to the treatment and care plan conjointly agreed between the 75 person living with HIV and the health worker" [5]. Optimum ART adherence, defined 76 as 95% and above of correctly taking medication is a primary determinant of VLS [6]. 77 Viral load suppression is viral load <1000 RNA copies per ml of blood and is critical in 78 prevention of transmission of HIV to sero-negative partner, disease progression, 79 opportunistic diseases, and AIDS-related deaths [5-7]. 80

However, consistent with the evidence, globally, high ART uptake and VLS rates are 81 only observed among the general population with adolescents reporting lower rates. 82 yet adolescents account for 5% of all PLHIV [3,8]. The rates are even lower among 83 ALHIV in sub-Sahara Africa (SSA) [1,3,9–11]. For instance, in 2021, VLS was only 84 30% among the 43% ALHIV on ART in SSA [12]. Furthermore, a systematic review 85 including studies conducted between 2010 and 2022, reported an ART adherence rate 86 of 65% and a VLS rate of 55% among ALHIV in SSA [13]. Similarly, studies conducted 87 in South Africa, Kenya, Tanzania, and Uganda have reported even lower ART 88 adherence rate ranging from 59% to 65% and VLS ranging from 22% to 73% [14–19]. 89

Several factors associated with ART adherence have been identified among studies.
These include age, sex, missing clinical appointment, presence of opportunistic
diseases, duration on ART, ART regimen, family support, type of health facility, World
Health Organization (WHO) clinical staging, VLS, and CD4-count [10,18,20–23].

The Kingdom of Eswatini formerly known as Swaziland has the highest Human 94 Immuno-deficiency Virus (HIV) prevalence of 27% globally with an incidence of 1.4 95 among those 15 years and above [24]. Females are mostly affected in the country with 96 an HIV prevalence of 32.5% compared to 20.4% among males [25]. Secondly, the HIV 97 prevalence is disproportionally high at 7.3% among female adolescents aged 15 to 19 98 99 years compared to their male counterparts at 3.9% [25]. HIV prevention and management is critical among adolescents not only in Eswatini, but in the sub-Saharan 100 Africa (SSA) region which is home to 90% of adolescents living with HIV (ALHIV) [3]. 101

Eswatini is among the first countries globally to meet the 95-95-95 (95% people living with HIV knowing their HIV status, 95% of these on ART and 95% of those on ART viral load suppressed) UNAIDS global targets in the general population ahead of the year 2030 [26]. Viral load suppression (VLS) was reported to be 96% as of 2022 in the country, from 91% in 2017 [25,26]. This has been attributed to the uninterrupted access and availability of antiretroviral therapy (ART) among those testing positive to HIV and programmes aimed at supporting ART adherence [27].

However, these positive gains are only observed among the general population while
ALHIV still present poor HIV treatment outcomes [28]. For instance, in 2017 Eswatini
reported 89% of the people living with HIV (PLHIV) on ART with 91% of them virally
suppressed. However, among ALHIV and young people, only 81.7% were on ART and
76.4% virally suppressed [25]. The discrepancies in viral load suppression rate among

adolescents and general population, are an indication of poor HIV prevention andmanagement, particularly poor ART adherence among ALHIV.

Unfortunately, there is limited HIV data on adolescents aged 10 to 19 years in Eswatini due to the wide description age-band of 15 to 24 years. Therefore, this study aimed to assess the level of ART adherence and associated factors among ALHIV aged 10 to 19 years on ART in Eswatini.

120

121 **2. Methods**

122 **2.1 Study design and population**

This was a retrospective study design which used data from the Eswatini Ministry of 123 Health, Health Management Information System [HMIS]. Data extraction was done 124 using a chart abstraction tool from the Client Management Information System (CMIS) 125 for adolescents who accessed care and tested HIV positive between the periods of 126 January 2017 and 30 September 2022. In 2017, Eswatini adopted and implemented 127 the universal test and treat guidelines and the same year, the CMIS was rolled out in 128 all the health facilities in the country [29]. The CMIS is a national electronic medical 129 130 record system aimed at tracking and caring for patients visiting health facilities in the country. The system consolidates all the medical history of patients into one data set 131 allowing for comprehensive health information of patients [29]. 132

133

134 2.2 Inclusion and exclusion criteria

This study included ALHIV who were enrolled and initiated in ART at age 10–19 with either vertical or horizontal HIV infection from 1st January 2017 to 30th September 2022. Only ALHIV and had been on ART for at least a month were included in this study. ALHIV who transitioned from paediatric care were excluded from this study. Secondly, ALHIV whose records had missing details of latest or current viral load (VL) result in the CMIS database were excluded from the study. Current or latest VL result was defined as the last available VL result.

142

143 **2.3 Ethical approval**

Approval to carry out the study was sought from the Eswatini Health and Human Research Review Board of the Ministry of Health and a waiver of consent was obtained from the Board (Protocol Reference Number: EHHRRB103/2022). A waiver not to acquire participants' informed consent was granted by the same board as this study involved secondary data analysis. Anonymity was maintained by de-identifying the data and assigning codes instead of names during the chart abstraction process.

150

151 2.4 Study setting

The data involved ALHIV enrolled in ART care from 1st January 2017 to 30th September 2022 in the Kingdom of Eswatini and registered in CMIS database. In 2015, adolescents accounted for 10% of all those in HIV treatment in the country [30]. Adolescents access care through a differential ART service delivery model which includes expert client offered by lay heath workers (LHWs) through Teen Clubs, multi-

months (3 and 6 months) refills, as well as the mainstream model [31,32]. The expert 157 client approach involves training LHWs on HIV treatment adherence, stigma and 158 disclosure, and HIV linkage to care and communication and counselling skills [33,34]. 159 The mainstream model also known as the standard of care model provides direct 160 patient monitoring by a nurse or a doctor mostly for patients newly initiated to ART, 161 with detectable VL, with ART adherence issues, or suspected treatment failure [35]. 162 163 In 2021, there were 10,153 ALHIV in the country while there were 81 Teen Clubs with 3,742 adolescents aged 10 to 19 years as members. The country has 327 health 164 165 facilities; one (1) national referral hospital, three (3) specialized hospitals, five (5) regional referral hospitals, five (5) health centres, six (6) public health units, 297 clinics 166 of which 65 are specialized clinics, and nine (9) private hospitals [36]. These health 167 facilities are distributed in the four regions (Hhohho, Manzini, Lubombo and 168 Shiselweni) of the country with the national referral hospital in the Hhohho region. 169

170

171 **2.5 Study sample**

A total 3,420 ALHIV aged 10 to 19 were enrolled on ART care between 1st January 2017 and 30th September 2022. Of these, 911 were included in the analysis as they met the inclusion criteria. Among the 911, some had missing data in one or more variables. We imputed the missing information using Multivariate Imputation by Chained Equations (MICE) for the variables we decided to include into the final multivariable regression model.

178

179 **2.6 Measurements**

All participants were followed for the period between January 2017 up until September 2022. Only ALHIV enrolled on ART between 1st January 2017 and September 2022 were included in this study. Our primary outcome was ART adherence defined as 95% of correctly taking ART which was estimated using the viral load suppression rate where viral load suppression was defined as viral load <1000 RNA copies per ml of blood, a standard VLS measurement used in Eswatini [37].

Predictor variables included: demographic and social factors (sex, age, region), HIV factors (age at diagnosis, baseline VL result, latest viral load result, ART start date, time on ART, model of ART care at initiation, latest or current model of ART care, regimen, CD4 count result, and WHO clinical staging), and facility factors (facility ownership). Baseline VL result was defined as the first VL result after a positive HIV diagnosis. Facility ownership included government, non-government, private and mission.

193

194 **2.7 Statistical analysis**

The dataset in Excel was exported to Stata for the data analysis, and the analysis was
done using the Stata statistical software, release 16, College Station, TX, Stata Corp
LLC.

Data analyses were conducted at descriptive, bivariate, and multivariable levels. Continuous variables (age, years at HIV diagnosis and years on ART) were presented as means with standard deviations and categorical variables were presented as frequencies and percentages. Differences in characteristics between ALHIV who were adherent versus those who were non-adherent were assessed using the chi-square

test. Associations between ART adherent and independent variables were examinedusing the Pearson' chi-square test.

Variables that were significantly associated with ART adherence at bivariate analysis at significance level of ≤ 0.2 were selected and included in the multivariable regression model. Age and sex were included despite their lack statistical significance. Due to high missing data in some of the variables, a Multiple Imputation by Chained Equation (MICE) was conducted to impute the missing values.

Backward elimination was used in building the final model whereby variables which did not contribute at p-value <0.05 were eliminated and a new model fitted. All variables that were significant at p<0.05 were kept in the final multivariable logistic regression model.

214

215 **3. Results**

3.1 Socio-demographic characteristics of participants

A total of 3420 medical records were reviewed of which only 911 were included in the analysis. Six-hundred-and-six (66.6%) adolescents were in the age group 15 to 19 years and 155 (60%) were females. The mean age of the ALHIV and on ART was 16.3 (SD 3.3). Majority (355; 39%) of the adolescents were from the Hhohho region while only 133 (15%) were from the Shiselweni region (Table 1).

222

3.2 Clinical and Treatment-Related Characteristics

The average age at diagnosis of adolescents was 14 years (SD 4.2). Most adolescents 224 (355; 70%) were enrolled under government owned health facilities while only 123 225 (13.5%) were enrolled in both private and non-government health facilities. 226 Government health facilities include both military and non-military health facilities. 227 Among adolescents with a recorded CD4 count results, 158 (60%) were on either 228 World Health Organization (WHO) clinical stage three or stage 4 as a baseline CD4 229 230 count result. As of 2022 (latest CD4 result), only 81 out of 141 adolescents with CD4 count result were on either of these stages. Seven-hundred-and-fifty-eight (83%) of 231 232 the adolescents had been on ART for 2 years and above. At baseline, 714 (88%) adolescents were virally load suppressed (Table 1). Overall, ART adherence was 233 88.5% among adolescents. The age group 15 to 19 years had higher adherence 234 (89.3%) compared to 10-14 years (86.9%). Hhohho region recorded 90.7% ART 235 adherence followed by Manzini (89.5%), Lubombo (87.50%), while Shiselweni had the 236 lowest adherence rate of 81.95% (Table 1). 237

238

239	Table 1: Characteristics of	of study participants	stratified by ART adherence
-----	-----------------------------	-----------------------	-----------------------------

Variable	Total N=911 ^a	Adherence (n, %)	Non-adherent (n, %)	p-value
Age group				
10-14	305	265 (86.89%)	40 (13.11%)	
15-19	606	541 (89.27%)	65 (10.73%)	0.287
Sex				
Female	551	490 (88.93%)	61 (11.07%)	
Male	360	316 (87.78%)	44 (12.22)	0.595
Region				
Hhohho	355	322 (90.70%)	33 (9.30%)	
Lubombo	184	161 (87.50%)	23 (12.5%)	
Manzini	239	214 (89.54%)	25 (10.46%)	0.052

Shiselweni	133	109 (81.95%)	24 (18.05%)	
Facility Ownership	,			
Government	641	567 (88.46%)	74 (11.54%)	0.945
NGO	123	108 (87.8%)	15 (12.2%)	
Faith-based	147	131 (89.12%)	16 (10.88%)	_
ART Duration				
<2 years	153	139 (90.85%)	14 (9.15%)	
≥2years	758	667 (87.99%)	91 (12.01%)	0.313
ART Regimen				
1 st Line	430	387 (90%)	43 (10%)	
2 nd Line	17	13 (76.5%)	4 (23.5%)	0.074
Baseline WHO Stag	ge			
-	104	91 (87.5%)	13 (12.5%)	
III-IV	158	142 (89.87%)	16 (10.13%)	0.549
Latest WHO Stage				
I-II	60	48 (80%)	12 (20.0%)	
III-IV	81	72 (88.89%)	9 (11.11%)	0.143
Baseline VLS				
No	98	64 (65.31%)	34 (34.69%)	
Yes	714	651 (91.18%)	63 (8.82%)	0.0000*
ART Model of Care	at Initiation			
Multi-Months	3	2 (66.67%)	1 (33.33%)	
Mainstream	416	371 (89.18%)	45 (10.87%)	0.393
Teen Clubs	37	34 (91.89%)	3 (8.11%)	
Current Model of A	RT Care			
Multi-Months	66	64 (96.97%)	2 (3.03%)	
Mainstream	433	379 (87.53%)	54 (12.47%)	
Teen Clubs 338		302 (89.35%)	36 (10.65%)	0.058
Fast Track	17	17 (100%)	0	

240

*Statistically significant

241

^a some sample sizes for variables may not add up to N due to missing data

242

Factors Associated with ART Adherence among 3.3 243

ALHIV 244

In the bivariate logistic regression analysis, Shiselweni region, viral load suppressed at initiation and mainstream at current ART care model were statistically significant predictors and were fitted in the multivariable logistic regression model (Table 2). In the multivariable regression model (Table 3), only Shiselweni and baseline or initial viral load suppressed were predictors of ART adherence.

The odds of adolescents from Shiselweni region were negatively associated (OR=0.54, 95%CI: 0.17-0.96) with ART adherence than adolescents from the other region of the country. The odds of adolescents with a suppressed baseline viral load were (OR=6.22, 95% CI: 4.13-10.56) almost six-fold likely to adhere to ART compared to those who were non-virally load suppressed (Table 3).

255

256 Table 2: Factors associated with ART adherence among ALHIV

Variable	OR p-value		95% CI	
Age	I			
10-14	Ref			
15-19	1.26	0.287	0.83-1.91	
Sex				
Female	Ref			
Male	0.89	0.595	0.59-1.35	
Region				
Hhohho	Ref			
Lubombo	0.72	0.249	0.41-1.26	
Manzini	0.88	0.639	0.51-1.52	
Shiselweni	0.47	0.008*	0.26-2.78	
Facility Owners	ship	1		

Government	Ref		
Non-government and Private	0.92	0.789	0.51-1.67
Faith-based	1.07	0.820	0.60-1.89
ART Duration			
<2 years	Ref		
≥2 years	0.74	0.315	0.41-1.33
Regimen			
1 st Line	Ref		
2 nd Line	0.36	0.086	0.11-1.16
Baseline VLS			
No	Ref		
Yes	5.49	0.000*	3.36-8.96
Baseline WHO st	age		
1-11	Ref		
III-IV	1.27	0.550	0.58-2.78
Latest WHO stage	6		
1-11	Ref		
III-IV	2	0.148	0.78-5.11
ART Model of Ca	re at Initiation		
Multi-Month	Ref		
Mainstream	4.12	0.251	0.37-46.37
Teen Club	5.67	0.204	0.39-82.24
Current ART Mod	lel of Care	I	
Multi-Month	Ref		
Mainstream	0.22	0.038*	0.05-0.92
Teen Club	0.26	0.070	0.06-1.12

*Statistically significant

258

Table 3: Multivariate Logistic Regression showing factors associated with ART 259

adherence among ALHIV 260

Variable	OR	p-value	95% CI
Age group			
10-14	Ref		
15-19	1.49	0.231	0.81-2.54
Sex			
Female	Ref		
Male	1.35	0.632	0.72-1.98
Region		I	I
Hhohho	Ref		
Lubombo	0.86	0.412	0.52-1.73
Manzini	0.90	0.512	0.63-1.79
Shiselweni	0.54	0.029*	0.17-0.96
Baseline VLS			
No	Ref		
Yes	6.22	0.001*	4.13-10.56
Current ART M	odel of Care		
Multi-Month	Ref		
Mainstream	1.23	0.661	0.67-2.23
Teen Clubs	0.94	0.623	0.58-2.14
Constant	tant 8.22		2.65-24.812
*01-11-11-1	ly significant		

261

*Statistically significant

262

263

4. Discussion

The study revealed the determinants of ART adherence among ALHIV in the Kingdom 265 of Eswatini. In this study, the mean age was 16.3 (SD 3.3) years with more females 266 (551, 60%) compared to males (360, 40%). On average, adolescents were initiated on 267 ART at the age of 14 years (SD 4.2). The study discovered that overall, ART 268 adherence among ALHIV was sub-optimal at 88.5% which is lower than the 95% ART 269 adherence rate required for suppressed viral load. When compared to other studies, 270 271 ART adherence among Swati adolescents was higher than in studies conducted among ALHIV in South Africa (65%), Kenva (76%) and Zimbabwe (28%) while 272 comparable with studies conducted in Nigeria (85%), Uganda (80%), Cameroon (83%) 273 274 [10.16.22.38–40]. These discrepancies among the countries could be due to the differences in outcome measurements, settings, sample sizes, and study designs as 275 explained in a study conducted in Ethiopia among children on ART [21]. 276

Nevertheless, an ART adherence rate below 95% is associated with unsuppressed 277 viral load which is further associated with opportunistic infections, drug resistance and 278 subsequently death [7]. For instance, in two studies conducted in South Africa, lower 279 ART adherence rate was statistically associated with increased opportunistic 280 infections and a two-fold (OR 1.98) likelihood of a detectable viral load [41,42]. Another 281 study conducted among ALHIV in South Africa reported that poor ART adherence was 282 also associated with virologic failure [43]. A study conducted in Liberia also revealed 283 that poor ART adherence was associated with loss to follow up and experiences of 284 drug side effects [44]. 285

286 Secondly, the study findings indicate that Shiselweni region is a predictor of poor ART 287 adherence compared to the other regions. This finding is not comparable to the

national findings which indicate that generally the Shiselweni region has the highest 288 HIV prevalence (26.5%) compared to the other regions but not statistically associated 289 with either viral load suppression or ART adherence [27]. The Swaziland HIV 290 Incidence measurement survey (SHIMS II) also reported that the different HIV 291 prevalence rates in the four regions of the country had no significant difference [25]. 292 However, findings of this study have revealed that there is an association between 293 294 ART adherence and region among ALHIV. This could be because previous studies were conducted among the general population or adult population while this study was 295 296 conducted among adolescent age group. Studies conducted in the Shiselweni region revealed that the universal test and treat (UTT) HIV program has been associated with 297 low retention to care partly due to status non-acceptance by those tested positive and 298 other factors such as transport costs and distance to health facilities [45-47]. The 299 Shiselweni region is ranked the poorest region in the country with high food and water 300 insecurities [46,48]. According to the Eswatini operational plan of 2020, the population 301 of the Shiselweni region is hard-to-reach with limited access to health services and 302 HIV prevention, control, and management services such as HIV testing and VL testing 303 since it is dynamic and very evanescent because of the recent influx and growth of 304 textile factories, and it harbours the main truck route and border gate [48]. The region 305 is therefore a hot spot for at-risk population [48]. The delayed initiation of ART due to 306 low testing in the Shiselweni region has been associated with poor ART outcomes 307 such as low viral load suppression among those who are eventually tested in the 308 region [46,47]. 309

According to studies conducted in Uganda and South Africa, retention to care was a positive predictor of ART adherence while a study conducted in South Africa also revealed that distance to health facilitator was statistically associated with ART

adherence [18,49]. Studies aimed at improving the financial capacity of ALHIV have 313 reported a positive association with retention to care and ART adherence [50–54]. This 314 has been facilitated by financial incentives aimed at assisting ALHIV with money for 315 honouring their hospital appointments, curbing food insecurities among others. For 316 instance, a study conducted in Uganda which was aimed at evaluating the efficacy of 317 economic incentive in improving ART outcomes such as viral load suppression and 318 319 adherence among ALHIV, presented a ten-fold increase among those receiving the economic incentive compared to standard of care [52]. However, status acceptability 320 321 has been reported to be associated with retention to care and ART adherence. In studies conducted in Zambia, Tanzania and South Africa, early status disclosure 322 among adolescents was associated with early acceptability of status and thus 323 treatment adherence [55–57]. Additionally, a study conducted by Cluver et al. (2015) 324 revealed that adolescents who had their status disclosed early were three times likely 325 to be retained in care and thus improved ART adherence [55]. However, other studies 326 have reported that adolescents whose status were revealed early were most likely to 327 miss medication doses due to treatment fatigue [49,58]. These contradicting findings 328 are justified by Ankrah et al. (2016) because of lack of support system among ALHIV 329 especially older adolescents as care-giver responsibility reduces and adolescents are 330 at a self-discovery stage [59]. Nevertheless, early treatment to initiation and adherence 331 332 to the treatment are critical in improving ART outcomes. WHO guidelines have established a positive association between early treatment initiation and improved 333 ART outcomes such as viral load suppression which are associated with optimum ART 334 adherence among those on ART [6]. Early initiation to ART is facilitated by the 335 availability of health services promoting HIV testing for early diagnosis and subsequent 336 treatment through the UTT approach [6,18]. 337

Lastly, the study revealed that baseline viral load suppression is a positive predictor 338 for ART adherence as revealed in other studies. Numerous studies have reported the 339 association between VLS and ART adherence. High viral load suppression is 340 positively associated with optimum ART adherence while non-viral load suppression 341 is a predictor for poor ART adherence [60–67]. For instance, in a study conducted in 342 Kenya, adolescents and children with a suppressed viral load were mostly likely to 343 344 adhere to treatment compared to those with a high viral load at ART initiation [68]. Furthermore, the UTT has been based on scientifically proven evidence that early 345 346 initiation to ART is effective in ensuring positive ART outcome such as reduced AIDS related morbidity and mortality [69–73]. The positive ART outcomes are enabled by 347 the low viral load which associated with ART adherence. 348

The strength of our study is that the results demonstrate the current ART adherence 349 level and key associated factors (demographic and social factors, HIV factors, and 350 facility factors) among ALHIV aged 10 to 19 years, a population group normally 351 reported with young adults and paediatrics. Secondly, since the study used the 352 national dataset, the study results can extrapolate the current ART adherence situation 353 in Eswatini specifically among ALHIV. Additionally, since secondary data was used. 354 355 recall and reporting bias were eliminated. Also, the data collection process was informed by professionalism and expertise, and not associated with research thus was 356 not subject to interview bias. Lastly, being the only study conducted among 357 358 adolescents within this age group, our study can contribute to informing policies, plans, and service delivery strategies for preventing and controlling poor ART adherence 359 among ALHIV in Eswatini. 360

Nonetheless, some limitations should be considered when interpreting the findings of
 this study. Firstly, this was a retrospective study that used secondary data for analysis

that was not intentionally collected for this study, and therefore limited the study in evaluating other predictors of ART adherence which were not covered in the records. Secondly, being a secondary dataset made the data prone to missing variables due to incomplete documentation. However, we are confident that the available data provide true estimation as it was captured by qualified health professionals.

368

369 **5.** Conclusions

In conclusion, our results demonstrate that ART adherence is sub-optimum among ALHIV in Eswatini despite the positive progress in attaining the 95-95-95 UNAIDS 2030 target by the general population. It is critical to better understand why adolescents have a sub-optimum adherence rate and device strategies aimed at improving ART adherence among ALHIV in Eswatini. These results highlight an urgent need to innovate strategies aimed at improving early ART initiation and intensive follow-up and support among ALHIV especially in the Shiselweni region.

377

6. List of abbreviations

AIDS, Acquired Immune Deficiency Syndrome; OR, Odds ratio; ART, Anti-Retroviral
Therapy; HIV, Human Immunodeficiency Virus; VL, Viral Load; VLS, Viral Load
suppression; ALHIV, Adolescents Living with HIV; PLHIV, People Living with HIV;
WHO, World Health Organization; CMIS, Client Management Information System;
SSA, sub-Sahara Africa; LHW, Lay Health Worker; UTT, Universal Test and Treat

7. Declaration

386	Ethics approval and consent to participate: Ethical approval for conducting the
387	study was sought from the Eswatini Health and Human Research Review Board of the
388	Ministry of Health and a waiver of consent was obtained from the Board since the
389	study used secondary data (Protocol Reference Number: EHHRRB103/2022).
390	Consent of publication: The Eswatini Health and Human Research Review Board of
391	the Ministry of Health granted the consent for publication of the findings of the study.
392	Availability of data and materials: Data underlying the findings of the study are
393	included in the paper.
394	Competing interests: The authors report that there was no conflict of interest in this
395	work.
396	Funding: The authors received no specific funding for this work.
397	Authors' contribution:
398	Conceptualization: Londiwe D. Hlophe, Peter S. Nyasulu, Constance S. Shumba
399	Dara curation: Londiwe D. Hlophe, Diribsa T. Bedada
400	Formal analysis: Londiwe D. Hlophe, Diribsa T. Bedada
401	Investigation: Londiwe D. Hlophe
402	Methodology: Londiwe D. Hlophe, Diribsa T. Bedada, Constance S. Shumba, Peter S.
403	Nyasulu
404	Writing-original draft preparation: Londiwe D. Hlophe

Writing- review and editing: Londiwe D. Hlophe, Diribsa T. Bedada, Constance S.
Shumba, Peter S. Nyasulu

Acknowledgement: The authors would like to thank the management and staff from
 the Ministry of Health; Health Management Information System for the support
 provided during the duration of the study. Special gratitude is also forwarded to Dr.
 Garikai Chemhaka for his valuable support throughout the study.

411

412

413 **References**

414	1.	UNAIDS. Global HIV & AIDS statistics —	- Fact sheet UNAIDS [Internet]. 2022
-----	----	----------------------------------------	----------------------------------------

415 [cited 2021 Aug 24]. Available from: https://www.unaids.org/en/resources/fact416 sheet

417 2. UNICEF. HIV Statistics - Global and Regional Trends - UNICEF DATA

418 [Internet]. 2021 [cited 2021 Aug 24]. Available from:

419 https://data.unicef.org/topic/hivaids/global-regional-trends/

420 3. UNICEF. HIV and AIDS in Adolescents - UNICEF Data [Internet]. 2021 [cited

421 2021 Jan 12]. Available from: https://data.unicef.org/topic/adolescents/hiv-aids/

- 422 4. UNAIDS. UNAIDS 2021 epidemiological estimates. 2021 [cited 2021 Aug 24].
- 423 Global HIV & AIDS statistics Fact sheet | UNAIDS. Available from:
- 424 https://www.unaids.org/en/resources/fact-sheet

425	5.	WHO. Global HIV Programme [Internet]. 2022 [cited 2022 Oct 7]. Available
426		from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-
427		programmes/hiv/treatment/service-delivery-adherence-retention
428	6.	WHO. WHO publishes new Consolidated HIV guidelines for prevention,
429		treatment, service delivery & monitoring [Internet]. 2021 [cited 2022 Aug 10].
430		Available from: https://www.who.int/news/item/16-07-2021-who-publishes-new-
431		consolidated-hiv-guidelines-for-prevention-treatment-service-delivery-
432		monitoring
433	7.	Hine P, Smith R, Eshun-Wilson I, Orrell C, Cohen K, Leeflang MMG, et al.
434		Measures of antiretroviral adherence for detecting viral non-suppression in
435		people living with HIV. Cochrane Database of Systematic Reviews.
436		2018;2018(7).
437	8.	UNAIDS. Global HIV & AIDS statistics — Fact sheet UNAIDS [Internet]. 2021
438		[cited 2021 Oct 15]. Available from: https://www.unaids.org/en/resources/fact-
439		sheet
440	9.	Adejumo OA, Malee KM, Ryscavage P, Hunter SJ, Taiwo BO. Contemporary
441		issues on the epidemiology and antiretroviral adherence of HIV-infected
442		adolescents in sub-Saharan Africa: A narrative review. J Int AIDS Soc
442 443		adolescents in sub-Saharan Africa: A narrative review. J Int AIDS Soc [Internet]. 2015;18(1):20049. Available from:
443	10.	[Internet]. 2015;18(1):20049. Available from:

- living with HIV in the Mbita Sub County Hospital, Homa Bay- Kenya. Afr Health
 Sci. 2021 May 23;21(1):18–24.
- 11. Amour MA, Shayo GA, Matee MM, Machumi L, Rugarabamu A, Aris EA, et al.
- 450 Predictors of mortality among adolescents and young adults living with HIV on
- 451 antiretroviral therapy in Dar es Salaam, Tanzania: a retrospective cohort study.
- 452 J Int AIDS Soc [Internet]. 2022 Feb 1 [cited 2022 Aug 3];25(2):25886.
- 453 Available from: /pmc/articles/PMC8863353/
- 12. Vreeman RC, Rakhmanina NY, Nyandiko WM, Puthanakit T, Kantor R. Are we
- 455 there yet? 40 years of successes and challenges for children and adolescents
- 456 living with HIV. J Int AIDS Soc [Internet]. 2021 Jun 1 [cited 2022 Jul 18];24(6):
- 457 e25759. Available from:
- 458 https://onlinelibrary.wiley.com/doi/full/10.1002/jia2.25759
- 459 13. Hlophe LD, Jacques L. Tamuzi, Constance S. Shumba PSN. Barriers and
- 460 facilitators to anti-retroviral therapy adherence among adolescents aged 10 to
- 461 19 years living with HIV in sub-Saharan Africa: A mixed-methods systematic
- review and meta-analysis. PLoS One [Internet]. 2023 Mar 18;18(5): e0276411.
- 463 Available from: http://dx.doi.org/10.1371/journal.pone.0276411
- 14. Bitwale NZ, Mnzava DP, Kimaro FD, Jacob T, Mpondo BCTT, Jumanne S.
- 465 Prevalence and Factors Associated with Virological Treatment Failure among
- 466 Children and Adolescents on Antiretroviral Therapy Attending HIV/AIDS Care
- and Treatment Clinics in Dodoma Municipality, Central Tanzania. J Pediatric
- 468 Infect Dis Soc. 2021 Mar;10(2):131–40.

469	15.	Brathwaite R, Ssewamala FM, Neilands TB, Okumu M, Mutumba M, Damulira
470		C, et al. Predicting the individualized risk of poor adherence to ART medication
471		among adolescents living with HIV in Uganda: the Suubi+Adherence study. J
472		Int AIDS Soc. 2021 Jun;24(6): e25756.
473	16.	Haghighat R, Toska E, Bungane N, Cluver L. The HIV care cascade for
474		adolescents initiated on antiretroviral therapy in a health district of South
475		Africa: a retrospective cohort study. BMC Infect Dis [Internet]. 2021 Jan [cited
476		2021 Aug 20];21(1):60. Available from: https://doi.org/10.1186/s12879-020-
477		05742-9
478	17.	Zhou S, Cluver L, Shenderovich Y, Toska E. Uncovering ART adherence
479		inconsistencies: An assessment of sustained adherence among adolescents in
480		South Africa. J Int AIDS Soc [Internet]. 2021 Oct;24(10): e25832. Available
481		from:
482		http://onlinelibrary.wiley.com/doi/10.1002/jia2.25832/full%7Chttps://doi.org/10.
483		1002/jia2.25832
484	18.	Cluver L, Pantelic M, Toska E, Orkin M, Casale M, Bungane N, et al.
485		STACKing the odds for adolescent survival: health service factors associated
486		with full retention in care and adherence amongst adolescents living with HIV
487		in South Africa. J Int AIDS Soc. 2018 Sep;21(9): e25176.
488	19.	Chory A, Callen G, Nyandiko W, Njoroge T, Ashimosi C, Aluoch J, et al. A Pilot
489		Study of a Mobile Intervention to Support Mental Health and Adherence
490		Among Adolescents Living with HIV in Western Kenya. AIDS Behav [Internet].
491		2022 Jul 22 [cited 2021 Nov 24];26(1):232–42. Available from:
492		https://doi.org/10.1007/s10461-021-03376-9

- 493 20. Watt MH, Maman S, Golin CE, Earp JA, Eng E, Bangdiwala SI, et al. Factors
- 494 associated with self-reported adherence to antiretroviral therapy in a
- 495 Tanzanian setting. AIDS Care. 2010 Mar;22(3):381–9.
- 496 21. GebreEyesus F, Mitku D, Tarekegn T, Temere B, Terefe T, Belete A, et al.
- 497 Levels of Adherence and Associated Factors Among Children on ART Over
- 498 Time in Northwest, Ethiopia: Evidence from a Multicenter Follow-Up Study.
- 499 HIV AIDS (Auckl). 2021; 13:829–38.
- 500 22. Bongfen MC, Torpey K, Ganle J, Ankomah A. Level of adherence and
- associated factors among HIV-positive adolescents on antiretroviral therapy in
- 502 Cameroon. Afr J AIDS Res. 2020 Dec;19(4):269–75.
- 23. Kim MH, Mazenga AC, Yu X, Ahmed S, Paul ME, Kazembe PN, et al. High
- self-reported non-adherence to antiretroviral therapy amongst adolescents
- 505 living with HIV in Malawi: Barriers and associated factors. J Int AIDS Soc.
- 506 2017;20(1):1–12.
- Justman J, Reed JB, Bicego G, Donnell D, Li K, Bock N, et al. Swaziland HIV
 Incidence Measurement Survey (SHIMS): a prospective national cohort study.
 Lancet HIV. 2017 Feb 1;4(2): e83–92.
- 510 25. SHIMS2. Swaziland Hiv Incidence Measurement Survey 2: a Population-
- 511 Based Hiv Impact Assessment. 2017;(July 2017):1–4. Available from:
- 512 http://phia.icap.columbia.edu/wp-
- 513 content/uploads/2017/11/Swaziland_new.v8.pdf
- 26. PEPFAR. Eswatini surpasses UNAIDS Fast-track Targets for treatment and
 viral suppression United States Department of State [Internet]. 2022 [cited

516 517		2022 Oct 14]. Available from: https://www.state.gov/eswatini-surpasses- unaids-fast-track-targets-for-treatment-and-viral-suppression/
518	27.	Eswatini Meets Global 95-95-95 HIV Target - Blog - The Global Fund to Fight
519		AIDS, Tuberculosis and Malaria [Internet]. [cited 2022 Oct 14]. Available from:
520		https://www.theglobalfund.org/en/blog/2020-09-14-eswatini-meets-global-95-
521		95-95-hiv-target/
522	28.	Nsibandze BS, Downing C, Poggenpoel M, Myburgh CPH. "I have been
523		rejected so many times" experiences of female adolescents living with HIV in
524		rural Manzini, Eswatini: A case study. Int J Afr Nurs Sci. 2021 Jan 1;
525		14:100307.
526	29.	Silvestre E. Measure Evaluation. 2017 [cited 2023 Aug 3]. p. 1 to 42
527		Implementing Swaziland's Client Management Information System:
528		Stakeholder's Views of the Process and Recommendations to Improve it.
529		Available from: https://www.measureevaluation.org/resources/publications/tr-
530		17-226.html
531	30.	Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B, et al.
532		Factors associated with virological failure and suppression after enhanced
533		adherence counselling, in children, adolescents and adults on antiretroviral
534		therapy for HIV in Swaziland. PLoS One [Internet]. 2015;10(2): e0116144.
535		Available from: http://dx.doi.org/10.1371/journal.pone.0116144
536	31.	Ness TE, Agrawal V, Guffey D, Small A, Simelane T, Dlamini S, et al. Impact
537		of using creative arts programming to support HIV treatment in adolescents
538		and young adults in Eswatini. AIDS Res Ther [Internet]. 2021 Dec 1 [cited

539 2022 Oct 23];18(1):1–7. Available from:

540 https://aidsrestherapy.biomedcentral.com/articles/10.1186/s12981-021-00423-

541

2

- 542 32. Ministry of Health. Kingdom of Eswatini. Guidelines for Differentiated Service
- 543 Delivery [Internet]. Mbabane; 2022 [cited 2022 Nov 13]. Available from:
- 544 https://cquin.icap.columbia.edu/wp-content/uploads/2022/07/Final_Policy-
- 545 Guidelines-for-Eswatini-Differentiated-Service-Delivery.pdf
- 546 33. Dlamini-Simelane T, Moyer E. Task shifting or shifting care practices? the
- ⁵⁴⁷ impact of task shifting on patients' experiences and health care arrangements
- in Swaziland. BMC Health Serv Res. 2017 Jan 10;17(1).
- 549 34. Ahmed C V., Weissinger G, Teitelman A, Sabelo Dlamini N, Patience Dlamini
- 550 N, Cebsile Dlamini T, et al. Expert client service delivery practices among

adolescents living with HIV in Eswatini: A thematic analysis. Child Youth Serv
Rev. 2022 Jan 1; 132:106309.

- 553 35. Ministry of Health. Swaziland. Swaziland Integrated HIV Management
- 554 Guidelines [Internet]. 2018 [cited 2022 Nov 15]. Available from:
- 555 http://swaziaidsprogram.org/wp-content/uploads/2021/07/2018-Integrated-HIV-
- 556 Management-Guidelines_final-1.pdf

557 36. Government of the Kingdom of Eswatini. Service Availability and Readiness

- Assessment (SARA), 2017 [Internet]. Ministry of Health,: Mbabane. Mbabane;
- 559 2017 [cited 2022 Oct 25]. Available from:
- 560 https://www.hst.org.za/publications/NonHST%20Publications/Eswatini%20SA
- 561 RA%20March%20(05%2004%202019).pdf

- 562 37. Ministry Of Health Kingdom of Swaziland. 2018-Integrated-HIV-Management-
- 563 Guidelines_final-1.pdf [Internet]. Mbabane; 2018 [cited 2022 Nov 13]. Available
- from: http://swaziaidsprogram.org/wp-content/uploads/2021/07/2018-
- 565 Integrated-HIV-Management-Guidelines_final-1.pdf
- 566 38. Sithole Z, Mbizvo E, Chonzi P, Mungati M, Juru TP, Shambira G, et al.
- 567 Virological failure among adolescents on ART, Harare City, 2017- a case-
- control study. BMC Infect Dis. 2018;18(1):1–8.
- 39. Natukunda J, Kirabira P, Ong KIC, Shibanuma A, Jimba M. Virologic failure in
- 570 HIV-positive adolescents with perfect adherence in Uganda: a cross-sectional
- study. Trop Med Health. 2019;47(1):1–10.
- 40. Meloni ST, Agaba P, Chang CA, Yiltok E, Oguche S, Ejeliogu E, et al.
- 573 Longitudinal evaluation of adherence, retention, and transition patterns of 574 adolescents living with HIV in Nigeria. PLoS One. 2020;15(7): e0236801.
- 575 41. Cluver LD, Toska E, Orkin FM, Meinck F, Hodes R, Yakubovich AR, et al.
- 576 Achieving equity in HIV-treatment outcomes: can social protection improve
- adolescent ART-adherence in South Africa? AIDS Care [Internet].
- 578 2016;28(sup2):73–82. Available from:
- 579 http://dx.doi.org/10.1080/09540121.2016.1179008
- 580 42. Zhou S, Cluver L, Shenderovich Y, Toska E. Uncovering ART adherence
- inconsistencies: An assessment of sustained adherence among adolescents in
- 582 South Africa. J Int AIDS Soc [Internet]. 2021 Oct 1 [cited 2023 Mar 4];24(10).
- 583 Available from: /pmc/articles/PMC8552454/

- 43. Cluver L, Meinck F, Toska E, Orkin FM, Hodes R, Sherr L. Multitype violence
 exposures and adolescent antiretroviral nonadherence in South Africa. AIDS.
 2018;32(8):975.
- 587 44. Gray KL, Kiazolu M, Jones J, Konstantinova A, Zawolo JSW, Gray WMH, et al.
- 588 Liberia adherence and loss-to-follow-up in HIV and AIDS care and treatment:
- 589 A retrospective cohort of adolescents and adults from 2016–2019. PLOS
- 590 Global Public Health. 2022;2(3).
- 591 45. Kerschberger B, Schomaker M, Jobanputra K, Kabore SM, Teck R, Mabhena
- 592 E, et al. HIV programmatic outcomes following implementation of the "Treat-
- 593 All" policy in a public sector setting in Eswatini: a prospective cohort study. J
- Int AIDS Soc [Internet]. 2020 Mar 1 [cited 2023 Feb 8];23(3). Available from:
- 595 https://pubmed.ncbi.nlm.nih.gov/32128964/
- 46. Horter S, Thabede Z, Dlamini V, Bernays S, Stringer B, Mazibuko S, et al. "Life
 is so easy on ART, once you accept it": Acceptance, denial and linkage to HIV
 care in Shiselweni, Swaziland. Soc Sci Med. 2017 Mar 1; 176:52–9.
- 599 47. Barbara Sibbald. Responding to Swaziland's dual epidemic. CMAJ [Internet].
- 600 2013 Jan 1 [cited 2023 Feb 8];185(1): E13–4. Available from:
- 601 https://www.cmaj.ca/content/cmaj/185/1/E13.full.pdf
- 48. PEPFAR. Eswatini Country Operational Plan (COP/ROP) 2020 Strategic
 Direction Summary. 2020.
- 49. Nabukeera-Barungi N, Elyanu P, Asire B, Katureebe C, Lukabwe I, Namusoke
- E, et al. Adherence to antiretroviral therapy and retention in care for

606		adolescents living with HIV from 10 districts in Uganda. BMC Infect Dis.
607		2015;15(1):1–10.
608	50.	Thirumurthy H, Ndyabakira A, Marson K, Emperador D, Kamya M, Havlir D, et
609		al. Financial incentives for achieving and maintaining viral suppression among
610		HIV-positive adults in Uganda: a randomised controlled trial. Lancet HIV. 2019
611		Mar;6(3): e155–63.
	F 4	Fahau OA Niau DE Katabara E Mfauraa DO Ullaraa N. Musarda N. at al
612	51.	Fahey CA, Njau PF, Katabaro E, Mfaume RS, Ulenga N, Mwenda N, et al.
613		Financial incentives to promote retention in care and viral suppression in
614		adults with HIV initiating antiretroviral therapy in Tanzania: a three-arm
615		randomised controlled trial. Lancet HIV. 2020 Nov;7(11): e762–71.
616	52.	Bermudez LG, Jennings L, Ssewamala FM, Nabunya P, Mellins C, McKay M.
617		Equity in adherence to antiretroviral therapy among economically vulnerable

adolescents living with HIV in Uganda. AIDS Care - Psychological and Socio-

619 Medical Aspects of AIDS/HIV [Internet]. 2016;28(sup2):83–91. Available from:

620 https://doi.org/10.1080/09540121.2016.1176681

53. Linnemayr S, Stecher C, Mukasa B. Behavioral economic incentives to

improve adherence to antiretroviral medication. Aids. 2017;31(5):719–26.

523 54. Bezabih T, Weiser SD, Menbere MS, Negash A, Grede N. Comparison of

624 treatment adherence outcome among PLHIV enrolled in economic

strengthening program with community control. AIDS Care. 2018

626 Mar;30(3):369–77.

627 55. Cluver LD, Hodes RJ, Toska E, Kidia KK, Orkin FM, Sherr L, et al. "HIV is like
628 a tsotsi. ARVs are your guns": Associations between HIV-disclosure and

629	adherence to antiretroviral treatment among adolescents in South Africa. Aids.
630	2015;29(April): S57–65.

- 631 56. Ramos J V, Mmbaga BT, Turner EL, Rugalabamu LL, Luhanga S,
- 632 Cunningham CK, et al. Modality of Primary HIV Disclosure and Association
- 633 with Mental Health, Stigma, and Antiretroviral Therapy Adherence in
- Tanzanian Youth Living with HIV. AIDS Patient Care STDS. 2018

635 Jan;32(1):31–7.

- 57. Stangl AL, Mwale M, Sebany M, Mackworth-Young CRS, Chiiya C, Chonta M,
- et al. Feasibility, Acceptability and Preliminary Efficacy of Tikambisane ('Let's

Talk to Each Other'): A Pilot Support Group Intervention for Adolescent Girls

Living with HIV in Zambia. J Int Assoc Provid AIDS Care. 2021;20.

- Merzel C, VanDevanter N, Irvine M. Adherence to antiretroviral therapy among
 older children and adolescents with HIV: A qualitative study of psychosocial
 contexts. AIDS Patient Care STDS. 2008;22(12).
- 59. Ankrah DNA, Koster ES, Mantel-Teeuwisse AK, Arhinful DK, Agyepong IA,
- Lartey M. Facilitators and barriers to antiretroviral therapy adherence among
 adolescents in Ghana. Patient Prefer Adherence. 2016; 10:329–37.

646 60. Xu L, Munir K, Kanabkaew C, Le Coeur S. Factors influencing antiretroviral

treatment suboptimal adherence among perinatally HIV infected adolescents in
Thailand. PLoS One. 2017;12(2):1–18.

- 649 61. Bvochora T, Satyanarayana S, Takarinda KC, Bara H, Chonzi P, Komtenza B,
- et al. Enhanced adherence counselling and viral load suppression in HIV
- 651 seropositive patients with an initial high viral load in Harare, Zimbabwe:

- Operational issues. PLoS One [Internet]. 2019 Feb 1 [cited 2023 Jan 24];14(2):
- e0211326. Available from:
- https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211326
- 655 62. Hussen S, Mama M, Mekonnen B, Yihune M, Shegaze M, Boti N, et al.
- 656 Predictors of Time to Viral Load Suppression of Adult PLWHIV on ART in Arba
- 657 Minch General Hospital: A Follow up Study. Ethiop J Health Sci [Internet].
- 658 2019 Nov 19 [cited 2023 Jan 24];29(6):751–8. Available from:
- 659 https://www.ajol.info/index.php/ejhs/article/view/191325
- 660 63. Diress G, Dagne S, Alemnew B, Adane S, Addisu A. Viral Load Suppression
- after Enhanced Adherence Counseling and Its Predictors among High Viral
- Load HIV Seropositive People in North Wollo Zone Public Hospitals, Northeast
- Ethiopia, 2019: Retrospective Cohort Study. AIDS Res Treat. 2020;2020.
- 664 64. Ross-Degnan D, Pierre-Jacques M, Zhang F, Tadeg H, Gitau L, Ntaganira J,
- 665 et al. Measuring adherence to antiretroviral treatment in resource-poor
- settings: The clinical validity of key indicators. BMC Health Serv Res. 2010;
- 667 10:42.
- 668 65. Chalker JC, Andualem T, Gitau LN, Ntaganira J, Obua C, Tadeg H, et al.
- 669 Measuring adherence to antiretroviral treatment in resource-poor settings: The
- 670 feasibility of collecting routine data for key indicators. BMC Health Serv Res
- 671 [Internet]. 2010 Feb 19 [cited 2022 Oct 27];10(1):1–11. Available from:
- https://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-10-43
- 673 66. Gebreeyesus F, Mitku D, Tarekegn T, Temere B, Terefe T, Belete A, et al.
- 674 Levels of Adherence and Associated Factors Among Children on ART Over

675		Time in Northwest, Ethiopia: Evidence from a Multicenter Follow-Up Study.
676		2021 [cited 2022 Oct 25]; Available from: https://doi.org/10.2147/HIV.S323090
677	67.	Ba J, Id V, Katsabola H, Bvumbwe Id M, Mhango J, Silverstein Id A, et al.
678		Factors associated with antiretroviral therapy adherence among adolescents
679		living with HIV in the era of isoniazid preventive therapy as part of HIV care.
680		PLOS Global Public Health [Internet]. 2022 Jun 2 [cited 2022 Oct 18];2(6):
681		e0000418. Available from:
682		https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.000
683		0418
684	68.	Kabogo J, Muniu E, Wamunyokoli F, Musoke R, Songok E. Evidence of
685		reduced treatment adherence among HIV infected paediatric and adolescent
686		populations in Nairobi at the onset of the UNAIDS Universal Test and Treat
687		Program. BMC Res Notes. 2018;11(1):1–7.
688	69.	Alhaj M, Amberbir A, Singogo E, Banda V, van Lettow M, Matengeni A, et al.
689		Retention on antiretroviral therapy during Universal Test and Treat
690		implementation in Zomba district, Malawi: a retrospective cohort study. J Int
691		AIDS Soc. 2019;22(2).
692	70.	Havlir D, Lockman S, Ayles H, Larmarange J, Chamie G, Gaolathe T, et al.
693		What do the Universal Test and Treat trials tell us about the path to HIV
694		epidemic control? Vol. 23, Journal of the International AIDS Society. 2020.
695	71.	Herce ME, Hoffmann CJ, Fielding K, Topp SM, Hausler H, Chimoyi L, et al.
696		Universal test-and-treat in Zambian and South African correctional facilities: a
697		multisite prospective cohort study. Lancet HIV. 2020;7(12).

698	72.	Mugenyi L, Nanfuka M, Byawaka J, Agaba C, Mijumbi A, Kagimu D, et al.
699		Effect of universal test and treat on retention and mortality among people living
700		with HIV-infection in Uganda: An interrupted time series analysis. PLoS One
701		[Internet]. 2022 May 1 [cited 2022 Oct 21];17(5): e0268226. Available from:
702		https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0268226
703	73.	Barlow-Mosha L, Musiime V, Davies MA, Prendergast AJ, Musoke P, Siberry
704		G, et al. Universal antiretroviral therapy for HIV-infected children: a review of
705		the benefits and risks to consider during implementation. J Int AIDS Soc. 2017
706		Jun;20(1):21552.

707